Shuttle Pharma (SHPH) is Set to Explode: Here’s Why
Shuttle Pharmaceuticals Holdings Inc. (NASDAQ:SHPH) is a clinical-stage specialty pharmaceutical company pioneering a novel approach to cancer treatment…
Buy the Dip? Universe Pharma (UPC) Could Surge After a Brutal 2024
Universe Pharmaceuticals Inc. (NASDAQ:UPC) is a China-based pharmaceutical company dedicated to the research, development, manufacturing, marketing, and sales…
Vaxcyte (PCVX) Could Be the Next Biotech Giant in the Vaccine Industry
Vaxcyte Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company at the forefront of a new wave in vaccine innovation.…
Relay Therapeutics (RLAY) Just Got FDA Backing—Here’s Why RLAY Stock Could Explode
Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage biotechnology company at the forefront of a new era in drug…
Werewolf Therapeutics (HOWL) Can Be the Next Biotech Moonshot
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is a cutting-edge biopharmaceutical company pioneering a transformative approach to cancer immunotherapy through its…
Verastem (VSTM)’s Cancer Drug Shows 83% Response Rate — Is this the Next 10x Biotech?
Verastem Oncology (NASDAQ:VSTM) is a dynamic, late-stage biopharmaceutical company dedicated to redefining the treatment landscape for some of…
Multikine’s 73% 5-Year Survival Rate Shocks Wall Street — Is CEL-SCI (CVM) the Next Big Winner?
CEL-SCI Corporation (NYSE:CVM) is a trailblazing clinical-stage biotechnology company that has spent decades at the forefront of immunotherapy…
Analysts Say Tango (TNGX) is Worth $10.43—Here’s Why It Might Go Even Higher
Tango Therapeutics Inc. (NASDAQ:TNGX) is a clinical-stage biotechnology company at the forefront of developing targeted cancer therapies using…
Is Prelude (PRLD) the Next Biotech Titan? Investors Are Watching this Stock Closely
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage biopharmaceutical company committed to transforming the treatment of cancer through the…
This $1 Stock Has a $6 Price Target—Is Pyxis (PYXS) the Best Cheap Biotech Play Right Now?
Pyxis Oncology Inc. (NASDAQ:PYXS) is a clinical-stage biotechnology company committed to redefining the landscape of cancer therapy through…
Foghorn Therapeutics (FHTX) is Quietly Building a Biotech Empire—Here’s Why Investors Are Watching
Foghorn Therapeutics Inc. (NASDAQ:FHTX) is a pioneering clinical-stage biotechnology company that is revolutionizing the treatment of cancer and…
ADC Therapeutics (ADCT): The Cancer-Fighting Biotech With a 200%+ Upside Potential
ADC Therapeutics SA (NASDAQ:ADCT) is a commercial-stage biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) for…
Amylyx (AMLX) Could Be the Biotech Underdog Set to Dominate Neurology in 2025
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a pioneering biopharmaceutical company committed to developing novel and life-extending treatments for people…
Alkermes (ALKS) Could Be the Best Neuroscience Stock to Own This Decade
Alkermes plc (NASDAQ:ALKS) is a fully integrated global biopharmaceutical company focused on the development, manufacture, and commercialization of…
Corbus (CRBP) has $149M in Cash & a Cancer Drug That Could Shock Wall Street
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) is a U.S.-based clinical-stage biopharmaceutical company focused on developing transformative therapies that address…
89bio (ETNB) is on Every Analyst’s Watchlist
89bio, Inc. (NASDAQ:ETNB) is a cutting-edge clinical-stage biopharmaceutical company pioneering the development of transformative therapies for serious liver…
60 Degrees Pharmaceuticals (XTP) Could Be the Next $10 Biotech
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative medicines…
4D Molecular Therapeutics (FDMT) Could Be the Next $5 Billion Gene Therapy Titan
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is a clinical-stage biotechnology company revolutionizing the field of genetic medicine through its…